The collaboration with Boehringer Ingelheim to develop a companion diagnostic for a new lung cancer treatment could enhance Guardant Health's market position and lead to increased adoption of its Guardant360® CDx. This partnership is likely to be viewed positively by investors, potentially driving the stock price up in the short term.